Olema Pharmaceuticals Inc. reported a net loss of $42.2 million for the third quarter ended September 30, 2025, compared to a net loss of $34.6 million in the same period in 2024. GAAP research and development expenses increased to $40.0 million from $33.2 million in the prior year quarter, mainly due to higher clinical development-related activities. Non-GAAP research and development expenses were $37.4 million, up from $28.9 million. The company ended the quarter with $329.0 million in cash, cash equivalents, and marketable securities. Key business developments included a new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancer, initiation of the OPERA-02 Phase 3 trial of palazestrant with ribociclib, and presentation of new data from a Phase 1b/2 study at ESMO 2025.